The Germans Trias i Pujol Research Institute (IGTP) and the Germans Trias Hospital have taken part for the first time in the Erasmus+ Programme with an ambitious project aimed at digitalizing student stays at the centre.
At the IGTP TODAY
The IGTP spin-off has developed a medical device to improve the diagnosis of acute ischaemic stroke. This is the second investment made within the BStartup Health Call for which 121 start-ups applied.
The device will identify possible obstructions in stents quickly and non-invasively. Nimble is a spin-off company of the Germans Trias i Pujol Research Institute (IGTP), the Universitat Politècnica de Catalunya (UPC) and the University of Barcelona (UB).
Biointaxis launches a 0.88M euro crowdfunding campaign to finance a curative therapy for Friedreich's Ataxia
Biointaxis is a spin-off of the IGTP led by Dr. Antoni Matilla-Dueñas. To date, the research has been financed with the support of patient associations, the founders themselves, La Caixa Foundation, the CDTI and the Ministry of Science and Innovation. The project, that received the European seal of excellence in 2020, is in the final phase of gene therapy after years of research progress and it is the only candidate with potential to cure the disease at the moment. This round aims to overcome the critical inflexion point - the demonstration of the biodistribution and safety of the therapy in non-human primates. The value of the company will increase considerably when this data is available in less than 1 year; the financing campaign is being carried out through the equity crowdfunding platform of Capital Cell.
Time is Brain, Spin-off company from the IGTP, closes its financing round in little more than an hour
The seed-funding round for the IGTP Spin-off Time is Brain has reached its financing objective in record time almost as soon as it opened. The company opened the round on the platform Capital Cell and has not only reached the goal of 640,000, but has passed it and received 800,000, the figure the spin-off had set as a maximum.
Time is Brain SL, a spin-off of the Germans Trias i Pujol Research Institute (IGTP), has just announced a round of equity seed-funding of 640,000 euros. The company is developing a medical device to improve the diagnostics of acute ischaemic stroke (AIS).
Two spin-off companies of the Germans Trias I Pujol Research Institute (IGTP) Biointaxis and Time is Brain have received the Seal of Excellence from the European Commission. The two companies with IGTP participation have opted for financing from the Horizon 2020 Programme and the award puts them in an advantageous position when requesting funds from other funding bodies.
A new IGTP spin-off to develop a medical device for improving the diagnostics and prognostics of acute ischaemic stroke
Researchers from the Germans Trias i Pujol Research Institute (IGTP) together with doctors from the hospital have developed a medical device to improve the diagnostics and prognostics of acute ischaemic stroke. The objective of the technology is to optimize the current clinical algorithm for this type of ictus so that medical staff can take the correct decisions for each patient, before and after admission to hospital. To develop the medical device the spin-off company Time is Brain, led by Dr Alicia Martínez-Piñeiro has been created by the IGTP.
The Innovation in Respiratory Infection and Tuberculosis Diagnosis research group led by Dr José Dominguez and Dr Cristina Prat Aymerich have started a collaboration with the team led by Dr Lluis Cuevas at the Liverpool School of Tropical Medicine to develop and validate new serological techniques for diagnosing COVID-19. The project is financed by the Wellcome Trust (UK).
The clinical trial will test whether the food supplement Manremyc® protects against infection with SARS-CoV-2 and starts this May. The Pharmaceutical company Reig Jofre is the sponsor of the trial. It is coordinated from the Germans Trias i Pujol Research Institute together with the IDIAP Jordi Gol Foundation. The trial will last three months and results are expected in October 2020.